GLP-1 Ra/Cagrilintide is a synthetic peptide blend meticulously prepared for scientific inquiry. This product, combining GLP-1 Ra and Cagrilintide, is synthesized with high purity for laboratory investigations. It is developed for use in various research applications. GLP-1 Ra/Cagrilintide is designated solely for research and development purposes.
GLP-1 Ra features a 39-amino-acid structure with modifications including 2-aminoisobutyric acid (Aib) and a C20 fatty diacid acylation, resulting in the molecular formula C221H342N46O68 and a weight of approximately 4,813 Da. Cagrilintide, a 37-amino-acid amylin analog with lipidation for extended half-life, has the formula C194H312N54O59S2 and a molecular weight around 4,409 Da. In combination, their structural enhancements promote albumin binding, conferring prolonged stability and resistance to degradation, with GLP-1 Ra's alpha-helical conformation aiding receptor interactions and cagrilintide's modifications minimizing aggregation.
Provided as a lyophilized powder blend, our product ensures purity exceeding 98% for each component, verified via HPLC and mass spectrometry. The mixture exhibits good solubility in aqueous buffers, but we recommend testing compatibility in your setups. Our focus on integrity means rigorous batch testing for consistency, so you can rely on it for precise experimental work.
The GLP-1 Ra/Cagrilintide combination merges two advanced peptides—GLP-1 Ra, a triple agonist targeting glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors, with cagrilintide, a long-acting amylin analog—to explore synergistic effects on metabolic regulation and energy homeostasis in research models. This blend is designed to leverage GLP-1 Ra's multi-receptor activation for enhanced glucose control and weight management alongside cagrilintide's satiety-promoting actions, offering a potent tool for in-vitro investigations into obesity, type 2 diabetes, and related pathways. As with all our peptides, the GLP-1 Ra/Cagrilintide combination is supplied exclusively for research purposes and in-vitro use only—not for human consumption or any clinical applications.
GLP-1 Ra operates as a balanced agonist at GLP-1, GIP, and glucagon receptors, enhancing insulin secretion, suppressing appetite, and boosting energy expenditure while mitigating gluconeogenesis. Cagrilintide mimics amylin by activating amylin and calcitonin receptors, slowing gastric emptying, promoting satiety, and reducing food intake without relying solely on incretin pathways. Together, they synergize to amplify metabolic effects, with GLP-1 Ra's multi-hormone targeting complemented by cagrilintide's amylin-like actions, potentially leading to superior weight loss and glucose control in models.
This dual mechanism involves cAMP signaling and neuronal modulation in appetite centers, offering a comprehensive approach to energy balance. We're always available to discuss how this interplay can inform your assays, breaking it down step by step.
In summary, the GLP-1 Ra/Cagrilintide combination stands as an innovative peptide blend for unraveling multifaceted metabolic pathways, harnessing triple agonism and amylin mimicry to advance research in weight management and diabetes models. Its synergistic potential excites our dedication to educational tools rooted in science and quality. Exclusively for in-vitro use, this blend reflects our approachable integrity in supporting your explorations. Let's partner in discovery, one experiment at a time.
The GLP-1 Ra/Cagrilintide combination is well-suited for in-vitro studies on obesity and type 2 diabetes, where it has been explored for additive effects on weight reduction and glycemic control in cellular models of adipocytes and pancreatic islets. Research in metabolic simulations demonstrates its potential to outperform single agonists, with investigations showing significant body weight decreases and improved insulin sensitivity.
Applications extend to cardiovascular and inflammatory models, probing reductions in visceral fat and HbA1c levels in tissue cultures. We suggest using it in time-course experiments to assess chronic metabolic adaptations, and our insights can help refine protocols for clarity and precision.
Store the lyophilized GLP-1 Ra/Cagrilintide blend at -20°C in a dry, light-protected container to preserve stability. Reconstitute with sterile bacteriostatic water or neutral buffer to 1-5 mg/mL, gently swirling to dissolve. Aliquot and freeze solutions, avoiding repeated freeze-thaw cycles.
Our testing ensures durability, but check pH before use. For guidance on your setups, we're here with logical suggestions.
The GLP-1 Ra/Cagrilintide combination merges two advanced peptides—GLP-1 Ra, a triple agonist targeting glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors, with cagrilintide, a long-acting amylin analog—to explore synergistic effects on metabolic regulation and energy homeostasis in research models. This blend is designed to leverage GLP-1 Ra's multi-receptor activation for enhanced glucose control and weight management alongside cagrilintide's satiety-promoting actions, offering a potent tool for in-vitro investigations into obesity, type 2 diabetes, and related pathways. As with all our peptides, the GLP-1 Ra/Cagrilintide combination is supplied exclusively for research purposes and in-vitro use only—not for human consumption or any clinical applications.
GLP-1 Ra operates as a balanced agonist at GLP-1, GIP, and glucagon receptors, enhancing insulin secretion, suppressing appetite, and boosting energy expenditure while mitigating gluconeogenesis. Cagrilintide mimics amylin by activating amylin and calcitonin receptors, slowing gastric emptying, promoting satiety, and reducing food intake without relying solely on incretin pathways. Together, they synergize to amplify metabolic effects, with GLP-1 Ra's multi-hormone targeting complemented by cagrilintide's amylin-like actions, potentially leading to superior weight loss and glucose control in models.
This dual mechanism involves cAMP signaling and neuronal modulation in appetite centers, offering a comprehensive approach to energy balance. We're always available to discuss how this interplay can inform your assays, breaking it down step by step.
In summary, the GLP-1 Ra/Cagrilintide combination stands as an innovative peptide blend for unraveling multifaceted metabolic pathways, harnessing triple agonism and amylin mimicry to advance research in weight management and diabetes models. Its synergistic potential excites our dedication to educational tools rooted in science and quality. Exclusively for in-vitro use, this blend reflects our approachable integrity in supporting your explorations. Let's partner in discovery, one experiment at a time.
GLP-1 Ra features a 39-amino-acid structure with modifications including 2-aminoisobutyric acid (Aib) and a C20 fatty diacid acylation, resulting in the molecular formula C221H342N46O68 and a weight of approximately 4,813 Da. Cagrilintide, a 37-amino-acid amylin analog with lipidation for extended half-life, has the formula C194H312N54O59S2 and a molecular weight around 4,409 Da. In combination, their structural enhancements promote albumin binding, conferring prolonged stability and resistance to degradation, with GLP-1 Ra's alpha-helical conformation aiding receptor interactions and cagrilintide's modifications minimizing aggregation.
Provided as a lyophilized powder blend, our product ensures purity exceeding 98% for each component, verified via HPLC and mass spectrometry. The mixture exhibits good solubility in aqueous buffers, but we recommend testing compatibility in your setups. Our focus on integrity means rigorous batch testing for consistency, so you can rely on it for precise experimental work.
The GLP-1 Ra/Cagrilintide combination is well-suited for in-vitro studies on obesity and type 2 diabetes, where it has been explored for additive effects on weight reduction and glycemic control in cellular models of adipocytes and pancreatic islets. Research in metabolic simulations demonstrates its potential to outperform single agonists, with investigations showing significant body weight decreases and improved insulin sensitivity.
Applications extend to cardiovascular and inflammatory models, probing reductions in visceral fat and HbA1c levels in tissue cultures. We suggest using it in time-course experiments to assess chronic metabolic adaptations, and our insights can help refine protocols for clarity and precision.
Store the lyophilized GLP-1 Ra/Cagrilintide blend at -20°C in a dry, light-protected container to preserve stability. Reconstitute with sterile bacteriostatic water or neutral buffer to 1-5 mg/mL, gently swirling to dissolve. Aliquot and freeze solutions, avoiding repeated freeze-thaw cycles.
Our testing ensures durability, but check pH before use. For guidance on your setups, we're here with logical suggestions.
